Evidence mapPaperPMID 37196705Full record

ArticleDiabetes research and clinical practice2023

Gaps in glucagon fills among commercially insured patients receiving a glucagon prescription.

Joseph R Herges, Jordan D Haag, Kimberly A Kosloski-Tarpenning, Kristin C Mara, Rozalina G McCoy

Open access · greenAbstract read
In one paragraph

Article in Diabetes research and clinical practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Joseph R HergesDepartment of Pharmacy, Mayo Clinic, Rochester, MN, United States. Electronic address: Herges.Joseph@mayo.edu.
Jordan D HaagDepartment of Pharmacy, Mayo Clinic, Rochester, MN, United States. Electronic address: Haag.Jordan@mayo.edu.
Kimberly A Kosloski-TarpenningDepartment of Pharmacy, Mayo Clinic Health System, Southeast Minnesota Region, Owatonna, MN, United States. Electronic address: Tarpenning.Kimberly@mayo.edu.
Kristin C MaraDivision of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, United States. Electronic address: Mara.Kristin@mayo.edu.
Rozalina G McCoyDivision of Community Internal Medicine, Geriatrics, and Palliative Care, Mayo Clinic, Rochester, MN, United States. Electronic address: McCoy.Rozalina@mayo.edu.
Mayo Clinic · USMayo Clinic Health System · USMayo Clinic in Arizona · US

Funding

NIDDK NIH HHS K23 DK114497
6 · The paper itself

Abstract

Glucagon is critically underutilized, and we explored whether this is due to inadequate glucagon prescribing or the patient's inability to fill prescriptions. Of 216 commercially insured, high-risk individuals with diabetes who were prescribed glucagon in our healthcare system, 142 (65.4%) had a claim indicating its fill within 30 days.

Indexed as

Diabetes MellitusGlucagonHumansPrescriptionsRetrospective StudiesUnited StatesGlucagonDiabetesGlucagonHypoglycemia

Identifiers

PMID37196705
PMCPMC10278149
OpenAlexW4376648662

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.